Ad hoc meeting with industry representatives

On 27 March 2020 (PM), EFSA met EuropaBio in the context of an ad hoc meeting with industry representatives. The meeting provided an opportunity to continue the constructive dialogue initiated last year on the risk assessment of ‘novel’ proteins with regard to their potential to cause celiac disease.

EuropaBio presented the latest considerations by the industry as regards the development and the maintenance of an appropriate database for sequence identity searches with celiac peptides. Both EuropaBio and EFSA also addressed the way forward with the safety assessment regarding celiac disease.

The meeting took place in a constructive atmosphere and marks an additional important step in enhanced dialogue among the parties.